CEO Cha Mi-sun of MEDIFAB — A First Mover Leading Anti-Aging Innovation Through Regenerative Medicine
“We create regeneration, not just simple fillers.” As the anti-aging industry shifts its focus from ‘cosmetics’ to ‘regeneration,’ MEDIFAB — a specialist in bio-regenerative medicine — is establishing itself at the forefront of this transformation. Built on a chitosan and decellularized extracellular matrix (dECM) regeneration platform, MEDIFAB has expanded its business scope beyond skincare into […]
“We create regeneration, not just simple fillers.” As the anti-aging industry shifts its focus from ‘cosmetics’ to ‘regeneration,’ MEDIFAB — a specialist in bio-regenerative medicine — is establishing itself at the forefront of this transformation. Built on a chitosan and decellularized extracellular matrix (dECM) regeneration platform, MEDIFAB has expanded its business scope beyond skincare into hair loss and joint regeneration, proving its growth potential by securing KRW 29 billion in investment and continuing its march toward a KOSDAQ listing. We met with CEO Cha Mi-sun, who has successfully bridged the gap between laboratory technology and industry, to hear about the current state and future potential of the regenerative medicine-based anti-aging sector.